Hologic (NASDAQ:HOLX) Lowered to Neutral at Citigroup

Citigroup lowered shares of Hologic (NASDAQ:HOLX) from a buy rating to a neutral rating in a research report sent to investors on Tuesday morning, Marketbeat reports. Citigroup currently has $85.00 price objective on the medical equipment provider’s stock, down from their prior price objective of $95.00.

A number of other research firms have also weighed in on HOLX. Stephens reiterated an overweight rating and issued a $92.00 price target on shares of Hologic in a research report on Tuesday, July 30th. Royal Bank of Canada reaffirmed a sector perform rating and issued a $82.00 target price on shares of Hologic in a report on Friday, August 16th. Evercore ISI raised their price target on Hologic from $76.00 to $78.00 and gave the company an in-line rating in a report on Tuesday, July 30th. Needham & Company LLC reaffirmed a buy rating and issued a $90.00 price objective on shares of Hologic in a research note on Tuesday, September 17th. Finally, StockNews.com downgraded Hologic from a strong-buy rating to a buy rating in a research note on Friday, September 27th. Five investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Hologic currently has a consensus rating of Moderate Buy and a consensus target price of $87.27.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $80.24 on Tuesday. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $18.73 billion, a PE ratio of 40.94, a price-to-earnings-growth ratio of 2.58 and a beta of 0.98. The firm’s 50 day moving average price is $81.24 and its 200-day moving average price is $77.39. Hologic has a twelve month low of $64.02 and a twelve month high of $84.67.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The business had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. During the same quarter last year, the company posted $0.93 EPS. The company’s revenue was up 2.7% compared to the same quarter last year. Equities research analysts expect that Hologic will post 4.09 EPS for the current year.

Insider Activity at Hologic

In related news, insider Brandon Schnittker sold 476 shares of the company’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the sale, the insider now owns 3,735 shares of the company’s stock, valued at $310,415.85. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, Director Christiana Stamoulis sold 9,039 shares of the firm’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the sale, the director now directly owns 45,472 shares of the company’s stock, valued at $3,615,024. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Brandon Schnittker sold 476 shares of Hologic stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the transaction, the insider now owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 18,280 shares of company stock valued at $1,469,973. 1.75% of the stock is owned by corporate insiders.

Institutional Trading of Hologic

Institutional investors have recently bought and sold shares of the stock. Massmutual Trust Co. FSB ADV increased its position in Hologic by 24.7% during the first quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock valued at $54,000 after acquiring an additional 137 shares during the last quarter. Graypoint LLC grew its holdings in Hologic by 3.9% during the 1st quarter. Graypoint LLC now owns 3,871 shares of the medical equipment provider’s stock valued at $302,000 after purchasing an additional 147 shares during the last quarter. Sequoia Financial Advisors LLC raised its position in Hologic by 2.3% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 7,215 shares of the medical equipment provider’s stock worth $536,000 after purchasing an additional 165 shares during the period. Parallel Advisors LLC lifted its stake in Hologic by 11.5% in the fourth quarter. Parallel Advisors LLC now owns 1,828 shares of the medical equipment provider’s stock worth $131,000 after purchasing an additional 189 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. boosted its position in shares of Hologic by 0.6% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 31,112 shares of the medical equipment provider’s stock valued at $2,425,000 after buying an additional 192 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.